Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis is under clinical development by CellTex Therapeutics and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis overview
Stem cell therapy is under development for the treatment of Alzheimer disease, rheumatoid arthritis and osteoarthritis. It is administered by intravenous and intraarticular route. The therapy comprises of autologous adipose-derived stem cells (AdMSCs).
CellTex Therapeutics overview
CellTex Therapeutics (CellTex) is an adult stem cell laboratory that provides stem cell banking and stem cell infusion services to their clients. It operates a bank to store adult stem cells for medical treatments. CellTex is headquartered in Houston, Texas, the US.
For a complete picture of Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis’s drug-specific PTSR and LoA scores, buy the report here.